Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy

BACKGROUND: Transwomen have an increased risk of HIV acquisition compared with other adults. Drug–drug interactions between pre-exposure prophylaxis (PrEP) and gender-affirming therapy are cited as a reason for poor PrEP uptake among transwomen. We evaluated plasma tenofovir and emtricitabine pharma...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Antimicrob Chemother
Autors principals: Cirrincione, Lauren R, Podany, Anthony T, Havens, Joshua P, Bares, Sara H, Dyavar, Shetty Ravi, Gwon, Yeongjin, Johnson, Tanner M, Amoura, N Jean, Fletcher, Courtney V, Scarsi, Kimberly K
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7177476/
https://ncbi.nlm.nih.gov/pubmed/32065631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkaa016
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars